Command Palette

Search for a command to run...

Failure Claims

Indexed failure dossiers with primary-source backing.

120 claims indexed
TitleTargetTrialPhaseFailure
Aug 26, 2026Emraclidine's M4 bet ended in a 698-patient extension nobody had a reason to finishEmraclidine (CVL-231, ABBV-1231, PF-06852231)CHRM4AbbVieNCT05443724Phase 2EfficacyOther
Aug 26, 2026CBX-12 turned a 10-patient signal into a randomized Phase 2 and lost itCBX-12 (alphalex pHLIP-exatecan peptide-drug conjugate)TOP1Cybrexa TherapeuticsNCT06315491Phase 2EfficacyOncology
Aug 26, 2026Checkpoint blockade accelerated renal medullary carcinomaIpilimumab plus nivolumabCTLA4M.D. Anderson Cancer CenterNCT03274258Phase 2EfficacyOncology
Aug 26, 2026LEAP-014 added response in metastatic ESCC and no survivalLenvatinib (added to pembrolizumab plus platinum chemotherapy)KDRMerck Sharp & Dohme LLCNCT04949256Phase 3EfficacyOncology
Aug 2, 2026Camrelizumab plus apatinib could not replace chemotherapy in first-line cervical cancerCamrelizumab (SHR-1210) plus apatinibPDCD1Sun Yat-Sen University Cancer CenterNCT04974944Phase 2EfficacyOncology
Aug 2, 2026Early hydrocortisone in sepsis stopped for futility, and the timing hypothesis is still untestedHydrocortisone (early low-dose intravenous)NR3C1Siriraj Hospital, Mahidol UniversityNCT06217939UnknownEfficacyInfectious Disease
Aug 1, 2026Eftilagimod alfa in metastatic breast cancer: AIPAC-003 stopped at the lead-in, and the Phase 3 it was meant to feed never openedEftilagimod alfaLAG3Immutep S.A.S.NCT05747794Phase 2/3SponsorOncology
Aug 1, 2026Rivoceranib in adenoid cystic carcinoma: RM-202 closed three years after its data, on an endpoint the disease rarely movesRivoceranibKDRElevar TherapeuticsNCT04119453Phase 2SponsorOncology
Jul 31, 2026ICT01 in advanced solid tumors: EVICTION-2 met its endpoints and was closed by an acquisitionICT01BTN3A1ImCheck Therapeutics, an Ipsen companyNCT05307874Phase 1/2SponsorOncology
Jul 31, 2026OMX-0407 in pretreated solid tumors: a SIK inhibitor closed the week after its expansion readout windowOMX-0407SIK3iOmx Therapeutics AGNCT05826600Phase 1/2SponsorOncology
Jul 30, 2026Avelumab plus lenvatinib in children with primary CNS tumors: an adult combination that did not translateAvelumab plus lenvatinibCD274EMD Serono Research & Development Institute, Inc.NCT05081180Phase 1EfficacyOncology
Jul 30, 2026Pioglitazone for sympathetic overactivity in CKD: the biomarker the trial was built on was not therePioglitazonePPARGThe University of Texas at ArlingtonNCT03471117UnknownBiomarkerOther
Jul 29, 2026Favezelimab in Hodgkin lymphoma: the LAG-3 trial that was closed by a colorectal cancer readoutFavezelimabLAG3Merck Sharp & Dohme LLCNCT03598608Phase 1/2SponsorOncology
Jul 29, 2026Siplizumab in new-onset type 1 diabetes: a dose-finding study that selected on the wrong half of the pharmacologySiplizumabCD2National Institute of Allergy and Infectious Diseases (NIAID)NCT05574335Phase 1/2Translational MismatchMetabolic
Jul 28, 2026Ulixertinib in metastatic uveal melanoma: an ERK inhibitor with no responders in stage 1UlixertinibMAPK1Dana-Farber Cancer InstituteNCT03417739Phase 2EfficacyOncology
Jul 28, 2026Rocatinlimab in prurigo nodularis: an OX40 program stopped by three Kaposi sarcoma casesRocatinlimabTNFRSF4AmgenNCT06527404Phase 3SafetyOther
Jul 27, 2026Patidegib topical gel stopped in non-Gorlin basal cell carcinoma when the endpoint ran out of eventsPatidegib topical gel 2% (IPI-926)SMOSol-Gel Technologies, Ltd.NCT04155190Phase 2Translational MismatchOncology
Jul 27, 2026innovaTV 205 closed by sponsor decision after five years, with the best-responding arm also the least tolerableTisotumab vedotin (HuMax-TF-ADC)F3Seagen, a wholly owned subsidiary of PfizerNCT03786081Phase 1/2SponsorOncology
Jul 27, 2026Evorpacept plus cetuximab and pembrolizumab stopped in MSS colorectal cancer after two fatal immune activation eventsEvorpacept (ALX148)CD47University of Colorado, DenverNCT05167409Phase 2SafetyOncology
Jul 27, 2026NuCana stopped NUC-3373 across 17 registered tumor types after enrolling 19 patientsNUC-3373 (fosifloxuridine nafalbenamide)TYMSNuCana plcNCT05714553Phase 1/2SponsorOncology
Jul 26, 2026ARTEMIS: terminal complement blockade failed cardiac surgery kidney injury a second timeRavulizumab (ALXN1210)C5Alexion Pharmaceuticals, Inc.NCT05746559Phase 3EfficacyOther
Jul 26, 2026GEN1047 and the B7-H4 T-cell engager problem: 179 patients, no posted resultGEN1047 (DuoBody-CD3-H101GxB7H4)VTCN1GenmabNCT05180474Phase 1/2SponsorOncology
Jul 11, 2026Tolinapant in relapsed/refractory PTCL: an IAP antagonist combination with no tolerable doseTolinapant (ASTX660)BIRC2Taiho Oncology, Inc.NCT05403450Phase 1SafetyOncology
Jul 11, 2026MK-6194 in non-segmental vitiligo: a Treg-selective IL-2 mutein that matched placeboMK-6194 (IL-2 mutein)IL2RAMerck Sharp & Dohme LLCNCT06113328Phase 2EfficacyOther
Jul 11, 2026Esmethadone (REL-1017) in major depressive disorder: a low-affinity NMDA blocker whose Phase 3 program stopped at interim re-estimationEsmethadone (REL-1017, dextromethadone)GRIN1Levomecor Inc. (Relmada Therapeutics REL-1017 program)NCT06011577Phase 3EfficacyOther
Jul 11, 2026Everolimus plus erlotinib in gemcitabine-refractory pancreatic cancer: mTOR blockade stopped for toxicity and futilityEverolimus (RAD001) plus erlotinibMTORM.D. Anderson Cancer Center (investigator-sponsored; everolimus from Novartis, erlotinib from OSI/Genentech)NCT00640978Phase 2EfficacyOncology
Jul 11, 2026TNO155 (batoprotafib) plus nazartinib in EGFR-mutant lung cancer: an SHP2 plus EGFR doublet ended for strategic reasons after eight yearsBatoprotafib (TNO155) plus nazartinib (EGF816)PTPN11Novartis PharmaceuticalsNCT03114319Phase 1SponsorOncology
Jul 8, 2026SAR443579: a CD123 NK-cell engager handed back after modest single-agent remission rates in relapsed AMLSAR443579 (IPH6101)IL3RASanofiNCT05086315Phase 1/2SponsorOncology
Jul 8, 2026SLC-3010: another CD122-biased IL-2 complex shelved in solid tumorsSLC-3010 (hIL-2/TCB2c)IL2SelecxineNCT05525247Phase 1/2SponsorOncology
Jul 8, 2026Obeticholic acid in biliary atresia: a pediatric FXR trial stopped by an adult safety signalObeticholic acid (OCA, Ocaliva)NR1H4Intercept PharmaceuticalsNCT06121375Phase 2/3SafetyOther
Jul 7, 2026MK-1167: a business-reason halt for an alpha7 nicotinic modulator in Alzheimer'sMK-1167 (alpha7 nicotinic acetylcholine receptor positive allosteric modulator)CHRNA7Merck Sharp & Dohme LLCNCT06721156Phase 2EfficacyNeurology
Jul 7, 2026TAK-280: a conditional B7-H3 x CD3 T-cell engager that reached cytokine release but not responseTAK-280 (B7-H3 x CD3e COBRA conditional bispecific T-cell engager)CD276TakedaNCT05220098Phase 1/2EfficacyOncology
Jul 6, 2026GEN1042 with radiotherapy: a CD40x4-1BB bispecific and no abscopal responsesGEN1042 (DuoBody-CD40x4-1BB, BNT312)CD40GenmabNCT05491317Phase 1/2EfficacyOncology
Jul 6, 2026KER-012 in pulmonary arterial hypertension: an activin ligand trap stopped for pericardial effusionsKER-012ACVR2BKeros Therapeutics, Inc.NCT05975905Phase 2SafetyCardiology
Jul 6, 2026Revumenib in colorectal and solid tumors: a menin inhibitor with zero responsesRevumenib (SNDX-5613)MEN1Syndax PharmaceuticalsNCT05731947Phase 1/2EfficacyOncology
Jul 1, 2026Etrasimod in Crohn's disease: CULTIVATE stops after the S1P modulator matches placeboEtrasimod (APD334)S1PR1PfizerNCT04173273Phase 2/Phase 3EfficacyImmunology
Jul 1, 2026Magrolimab in classic Hodgkin lymphoma: a responding trial closed when the CD47 program collapsedMagrolimab (Hu5F9-G4)CD47Ranjana Advani (Stanford University), with Merck Sharp & DohmeNCT04788043Phase 2SponsorOncology
Jun 30, 2026Lebrikizumab in asthma: an anti-IL-13 effect that would not replicateLebrikizumabIL13Hoffmann-La RocheNCT01875003Phase 3EfficacyImmunology
Jun 30, 2026Belapectin in MASH cirrhosis: a subgroup that did not survive its own confirmatory trialBelapectin (GR-MD-02)LGALS3Galectin Therapeutics Inc.NCT04365868Phase 2/3EfficacyCardiology
Jun 30, 2026Valiltramiprosate (ALZ-801) in APOE4/4 Alzheimer's: the oral anti-oligomer bet winds downValiltramiprosate (ALZ-801)APPAlzheon Inc.NCT06304883Phase 3EfficacyNeurology
Jun 29, 2026SAR442501 in achondroplasia: an anti-FGFR3 antibody dropped at 16 patients in a crowded fieldSAR442501FGFR3SanofiNCT06067425Phase 2SponsorOther
Jun 29, 2026Brensocatib in hidradenitis suppurativa: a DPP1 inhibitor that worked in bronchiectasis and lost to placebo hereBrensocatibCTSCInsmed IncorporatedNCT06685835Phase 2EfficacyOther
Jun 26, 2026Pegargiminase in leiomyosarcoma: ARGSARC ends a Phase 3 where the active arm gave up chemotherapyPegargiminase (ADI-PEG 20)ASS1Polaris GroupNCT05712694Phase 3EfficacyOncology
Jun 26, 2026SGN-MesoC2 and the mesothelin question: Pfizer shelves a TOP1 ADC in a target class that keeps disappointingSGN-MesoC2 (PF-08052666)MSLNSeagen (Pfizer)NCT06466187Phase 1SponsorOncology
Jun 24, 2026Brazikumab worked against IL-23 in Crohn's disease, then lost a portfolio decisionBrazikumab (MEDI2070)IL23AAstraZenecaNCT03759288Phase 2/3SponsorImmunology
Jun 24, 2026Bemarituzumab's FGFR2b benefit lived in gastric cancer, so the solid-tumor basket was cutBemarituzumabFGFR2AmgenNCT05325866Phase 1/2SponsorOncology
Jun 23, 2026BND-35 and the myeloid checkpoint that was tested in the wrong tumorsBND-35LILRB4Biond BiologicsNCT06274437Phase 1SponsorOncology
Jun 23, 2026CLN-617 and the limits of anchoring two cytokines inside a tumorCLN-617IL12BCullinan TherapeuticsNCT06035744Phase 1EfficacyOncology
Jun 22, 2026PRS-344/S095012 in solid tumors: a 4-1BB/PD-L1 bispecific stopped in Phase 1PRS-344/S095012TNFRSF9Servier Bio-Innovation LLCNCT05159388Phase 1/2SponsorOncology
Jun 22, 2026GSK3965193 in chronic hepatitis B: a PAPD5/7 RNA destabilizer dropped for bepirovirsenGSK3965193PAPD5GlaxoSmithKlineNCT05330455Phase 1/2SponsorInfectious Disease
Jun 22, 2026Spesolimab in hidradenitis suppurativa: an IL-36 receptor program that worked in pustular psoriasis and stalled hereSpesolimabIL1RL2Boehringer IngelheimNCT06241573Phase 2/3Translational MismatchOther
Jun 22, 2026Pociredir in sickle cell disease: an EED inhibitor halted by a PRC2 class-safety verdictPociredirEEDFulcrum TherapeuticsNCT07431398Phase 1SafetyOther
Jun 20, 2026BE-101 in hemophilia B: a genetically airtight target dropped for strategic reasonsBE-101 (engineered B-cell secreting Factor IX-Padua)F9Be BiopharmaNCT06611436Phase 1/2SponsorOther
Jun 20, 2026Vidutolimod in first-line metastatic melanoma: the randomized TLR9 bet that was called offVidutolimod (CMP-001)TLR9Regeneron PharmaceuticalsNCT04695977Phase 2/3SponsorOncology
Jun 19, 2026XMT-2056, a HER2-directed STING-agonist ADC, ends in Phase 1 after a fatal dose-escalation signal and an acquisitionXMT-2056ERBB2Day One BiopharmaceuticalsNCT05514717Phase 1SponsorOncology
Jun 19, 2026NX-13, NLRX1, and the limits of an agonist with almost no human genetic support in ulcerative colitisNX-13NLRX1AbbVieNCT05785715Phase 2SponsorImmunology
Jun 17, 2026A non-depleting anti-CD19 antibody in rheumatoid arthritis: the LY3541860 interim futilityLY3541860CD19Eli Lilly and CompanyNCT06859294Phase 2EfficacyImmunology
Jun 17, 2026Canakinumab plus chemoimmunotherapy in first-line NSCLC: the CANOPY-1 efficacy failureCanakinumab (ACZ885)IL1BNovartis PharmaceuticalsNCT03631199Phase 3EfficacyOncology
Jun 15, 2026Amlitelimab worked in eczema and was dropped in alopecia areataAmlitelimabTNFSF4SanofiNCT06444451Phase 2SponsorImmunology
Jun 15, 2026BBI-825 stopped on its own metabolism, not on RNR biologyBBI-825RRM1Boundless Bio, Inc.NCT06299761Phase 1/2Translational MismatchOncology
Jun 15, 2026Acasunlimab in melanoma: a PD-L1x4-1BB bispecific shelved before the question could be testedAcasunlimabTNFRSF9GenmabNCT06984328Phase 2SponsorOncology
Jun 15, 2026Poziotinib in exon 20 NSCLC: when preclinical potency outran the therapeutic windowPoziotinibERBB2Spectrum Pharmaceuticals, IncNCT03318939Phase 2Translational MismatchOncology
Jun 15, 2026Vidutolimod in skin cancers: a TLR9 agonist whose response collapsed after checkpoint failureVidutolimodTLR9Regeneron PharmaceuticalsNCT04916002Phase 2SponsorOncology
Jun 12, 2026BBI-355 and the ecDNA bet: a first-in-class CHK1 inhibitor halted on clinical and market groundsBBI-355CHEK1Boundless BioNCT05827614Phase 1SponsorOncology
Jun 12, 2026Brimarafenib plus mirdametinib: a vertical MAPK doublet stopped for tolerabilityBrimarafenib (BGB-3245) plus mirdametinibBRAFSpringWorks TherapeuticsNCT05580770Phase 1/2SafetyOncology
Jun 11, 2026Tiragolumab in resected NSCLC: an adjuvant trial closed by the class-wide TIGIT collapseTiragolumabTIGITHoffmann-La RocheNCT06267001Phase 3EfficacyOncology
Jun 11, 2026Obeticholic acid plus bezafibrate in PBC: a long-term safety extension ended by a market withdrawalObeticholic acid (OCA) + bezafibrate fixed-dose combinationNR1H4Intercept PharmaceuticalsNCT06488911Phase 3SafetyOther
Jun 11, 2026ASP1570 in advanced solid tumors: a DGK-zeta brake that read clean in mice and flat in patientsASP1570DGKZAstellas Pharma Global Development, Inc.NCT05083481PHASE1_2EfficacyOncology
Jun 11, 2026Epetraborole in treatment-refractory MAC: a Phase 2 PRO signal that Phase 3 erasedEpetraboroleleuSAN2 Therapeutics, IncNCT05327803PHASE2_3EfficacyInfectious Disease
Jun 11, 2026Aticaprant in MDD: target engagement held, clinical efficacy did notAticaprantOPRK1Janssen Research & Development, LLCNCT06635135Phase 3EfficacyOther
Jun 9, 2026Soticlestat in Dravet and Lennox-Gastaut syndrome: a CH24H bet that cleared Phase 2 and missed in Phase 3Soticlestat (TAK-935)CYP46A1TakedaNCT05163314Phase 3EfficacyOther
Jun 9, 2026Vodobatinib in dementia with Lewy bodies: a c-Abl program stopped by the readout next doorVodobatinib (K0706)ABL1Georgetown UniversityNCT03996460Phase 2Translational MismatchNeurology
Jun 7, 2026Lenvatinib plus pembrolizumab in melanoma brain metastases: an antiangiogenic resensitization bet that produced almost no intracranial responsesLenvatinibKDRYale University (collaborator: Merck Sharp & Dohme)NCT04955743Phase 2EfficacyOncology
Jun 7, 2026PF-07265807, a dual AXL and MERTK inhibitor, discontinued in Phase 1 solid tumors: a genetically unanchored TAM-kinase bet left without a readoutPF-07265807MERTKPfizerNCT04458259Phase 1SponsorOncology
Jun 6, 2026INCB099280, an oral PD-L1 inhibitor, dropped in Part 1 as Incyte cut its checkpoint pipelineINCB099280 plus axitinibCD274Incyte CorporationNCT05949632Phase 1/2SponsorOncology
Jun 6, 2026Alpelisib plus olaparib failed to beat chemotherapy in platinum-resistant ovarian cancerAlpelisib (BYL719) plus olaparibPIK3CANovartis PharmaceuticalsNCT04729387Phase 3EfficacyOncology
Jun 5, 2026JNJ-95475939, a bispecific IL-4Rα x IL-31 antibody, stopped for futility in atopic dermatitis at the DUPLEX-AD interimJNJ-95475939IL31Janssen Research & Development, LLC (Johnson & Johnson)NCT06881251Phase 2EfficacyOther
Jun 5, 2026VIALE-T, a Phase 3 venetoclax plus azacitidine maintenance trial after transplant in AML, ended on strategic groundsvenetoclaxBCL2AbbVieNCT04161885Phase 3SponsorOncology
Jun 3, 2026BGB-53038, a pan-KRAS inhibitor, shelved at Phase 1 as BeOne pivots to a degraderBGB-53038KRASBeOne MedicinesNCT06585488Phase 1SponsorOncology
Jun 3, 2026Eciskafusp alfa (PD1-IL2v): a Phase 1 solid-tumor program stopped at a 4.4% predicted chance of clearing its ORR gateEciskafusp alfa (RO7284755, RG6279)IL2RBHoffmann-La RocheNCT04303858Phase 1EfficacyOncology
Jun 3, 2026Linaprazan glurate: a Phase 3 reflux maintenance trial withdrawn before enrollment on a validated targetLinaprazan glurate (X842)ATP4ACinclus Pharma Holding ABNCT07313774Phase 3SponsorOther
Jun 3, 2026Deucravacitinib in hidradenitis suppurativa: a TYK2 pilot that lost its funding at seven patientsDeucravacitinib (BMS-986165)TYK2Beth Israel Deaconess Medical Center (collaborator: Bristol-Myers Squibb)NCT05997277Phase 2SponsorOther
Jun 3, 2026GSK1070806 in atopic dermatitis: when a 44 percent placebo response ends an IL-18 programGSK1070806IL18GlaxoSmithKlineNCT05999799Phase 2EfficacyOther
Jun 2, 2026Inhaled treprostinil in PH-COPD: PERFECT stops for harm and the extension closesInhaled treprostinilPTGIRUnited TherapeuticsNCT03794583Phase 3SafetyCardiology
Jun 2, 2026Delocamten in obstructive HCM: BMS halts its own backup myosin inhibitorDelocamten (MYK-224 / BMS-986435)MYH7Bristol-Myers SquibbNCT05556343Phase 2SponsorCardiology
Jun 2, 2026PRO1107, a PTK7 antibody-drug conjugate, ended at 33 patients on benefit-riskPRO1107 (GEN1107)PTK7GenmabNCT06171789Phase 1/2Translational MismatchOncology
Jun 2, 2026Nogapendekin alfa inbakicept met its lymphocyte surrogate but lost its first-line NSCLC Phase 3nogapendekin alfa inbakicept (N-803)IL15ImmunityBio, Inc.NCT03520686Phase 3SponsorOncology
Jun 1, 2026ONO-7018 and the MALT1 paracaspase: a first-in-class inhibitor stopped at nine patientsONO-7018MALT1Ono Pharmaceutical Co., Ltd.NCT05515406Phase 1SponsorOncology
Jun 1, 2026GS-0272 and BTLA agonism: a checkpoint agonist that could not show efficacy in rheumatoid arthritisGS-0272BTLAGilead SciencesNCT06031415Phase 1EfficacyImmunology
May 31, 2026Certepetide, an NRP1-engaging tumor-penetration peptide, was halted in the BOLSTER cholangiocarcinoma trialcertepetideNRP1Lisata TherapeuticsNCT05712356Phase 2Translational MismatchOncology
May 31, 2026BGB-45035, an oral IRAK4 degrader, was terminated in rheumatoid arthritis for insufficient benefitBGB-45035IRAK4BeiGeneNCT07100938Phase 2EfficacyImmunology
May 31, 2026CRD-4730, a CaMKII inhibitor for CPVT1, was halted at 7 patients on a business decisionCRD-4730CAMK2DCardurion Pharmaceuticals, Inc.NCT06005428Phase 2SponsorOther
May 31, 2026Bemcentinib plus pacritinib in lung adenocarcinoma ended at 4 patients on drug-supply limitsbemcentinibAXLThe University of Texas Health Science Center at San AntonioNCT06516887Phase 1/2SponsorOncology
May 30, 2026Govorestat in CMT-SORD: the fifth aldose-reductase shot at a SORD-driven neuropathy gets shelved before enrollmentGovorestatAKR1B1Applied Therapeutics, Inc.NCT07191912PHASE_3SponsorOther
May 30, 2026NBI-921352 in SCN8A-DEE: the only Nav1.6-selective clinical asset gets terminated in extension at n=8NBI-921352 (zandatrigine)SCN8ANeurocrine BiosciencesNCT05226780PHASE_2SponsorOther
May 25, 2026Abemaciclib in HPV-negative HNSCC AIM window trial halted after standard-of-care shift to neoadjuvant immunotherapyAbemaciclib (LY2835219, VERZENIO)CDK6University of ArizonaNCT04169074Phase 2SponsorOncology
May 25, 2026Olutasidenib plus azacitidine in IDH1-mutant higher-risk MDS, CMML, and advanced MPNOlutasidenib (FT-2102, REZLIDHIA)IDH1M.D. Anderson Cancer CenterNCT06597734Phase 2SponsorOncology
May 24, 2026ARO-ANG3 (zodasiran) Phase 2 in HoFH: positive LDL signal, then a quiet business-decision shutdownARO-ANG3 (zodasiran)ANGPTL3Arrowhead PharmaceuticalsNCT05217667Phase 2SponsorMetabolic
May 24, 2026AMAG-423 in severe preeclampsia: a digoxin immune Fab Phase 2b/3a stopped by the DSMB for futilityAMAG-423 (digoxin immune Fab)ATP1A1AMAG Pharmaceuticals, Inc.NCT03008616PHASE2_PHASE3EfficacyOther
May 23, 2026Azenosertib in metastatic triple-negative breast cancer: ZAP-IT closes after Zentalis pulls the program over safetyAzenosertib (ZN-c3)WEE1Filipa Lynce, MD (Dana-Farber Cancer Institute) / Zentalis PharmaceuticalsNCT06351332PHASE1_2SafetyOncology
May 23, 2026MT-1186 oral edaravone in ALS: a Phase 3b extension follows its parent into futilityMT-1186 (oral edaravone)SOD1Tanabe Pharma America, Inc.NCT05151471Phase 3EfficacyNeurology
May 22, 2026OPC-167832 in DBOS and PBOS regimens: the 3-month tuberculosis target slips againOPC-167832 (quabodepistat) within DBOS and PBOS regimensDPRE1Gates Medical Research InstituteNCT05971602Phase 2EfficacyInfectious Disease
May 22, 2026BG-60366 in EGFR-mutant NSCLC: a chimeric degrader retired after 33 patients in a saturated landscapeBG-60366EGFRBeOne Medicines (formerly BeiGene)NCT06685718Phase 1SponsorOncology
May 21, 2026Lerociclib in HR+/HER2- advanced breast cancer: a clean strategic shutdown in a saturated classLerociclib (G1T38)CDK6EQRx, Inc.NCT05085002Phase 2SponsorOncology
May 21, 2026DS-2325a in Netherton syndrome: an anti-KLK5 monoclonal antibody shut down on business groundsDS-2325aKLK5Daiichi SankyoNCT05979831PHASE1_PHASE2SponsorOther
May 20, 2026INB03 in COVID-19 ARDS: Why a Selective Soluble TNF Strategy Did Not Separate From PlaceboINB03 (XPro1595, pegipanermin)TNFINmune Bio, Inc.NCT04370236PHASE2_3EfficacyInfectious Disease
May 20, 2026TOL-3021 SUNRISE: a proinsulin DNA vaccine ran out of biological roomTOL-3021 (BHT-3021)INSTolerion, Inc.NCT03895437Phase 2EfficacyMetabolic
May 20, 2026Daxdilimab in discoid lupus: Amgen walks away from the ILT7 chairDaxdilimab (HZN-7734, MEDI-7734, VIB7734)LILRA4Amgen (formerly Horizon Therapeutics, originally Viela Bio)NCT05591222Phase 2SponsorImmunology
May 20, 2026HexaBody-CD38 (GEN3014) in Relapsed/Refractory Multiple Myeloma: A Better Antibody, A Saturated MarketGEN3014 (HexaBody-CD38)CD38GenmabNCT04824794PHASE1_2SponsorOncology
May 19, 2026MAGNET: lithium in UNC13A-stratified ALS fails the confirmatory testLithium carbonateGSK3BStichting TRICALS FoundationNCT06008249Phase 3BiomarkerNeurology
May 19, 2026Icovamenib in Type 1 Diabetes: Biomea closes COVALENT-112 after a Phase 2 that was never powered to landIcovamenib (BMF-219)MEN1Biomea Fusion Inc.NCT06152042Phase 2SponsorMetabolic
May 19, 2026AdvanTIG-302: ociperlimab and the slow collapse of TIGIT in NSCLCOciperlimab (BGB-A1217)TIGITBeiGeneNCT04746924Phase 3EfficacyOncology
May 19, 2026Onfasprodil (MIJ821) in MDD with suicidal ideation: an NR2B-selective NMDA antagonist that worked for TRD but matched placebo at 24 hoursOnfasprodil (MIJ821)GRIN2BNovartis PharmaceuticalsNCT04722666Phase 2EfficacyNeurology
May 18, 2026BG-89894 (SYH2039): BeOne pulls a MAT2A inhibitor before it can reportBG-89894 (SYH2039)MAT2ABeOne Medicines (BeiGene)NCT06568614Phase 1SponsorOncology
May 18, 2026Tenecteplase in central retinal artery occlusion: REVISION halts a Phase 3 thrombolysis trial for futilityTenecteplase (originally alteplase, switched in protocol V04)PLATUniversity Hospital TuebingenNCT04965038Phase 3EfficacyNeurology
May 18, 2026Tusamitamab ravtansine in 2L NSCLC: when the antigen is real but the ADC is not enoughTusamitamab ravtansine (SAR408701)CEACAM5SanofiNCT04154956Phase 3EfficacyOncology
May 18, 2026IMSA101 and the quiet retirement of the STING-agonist hypothesis in oncologyIMSA101STING1ImmuneSensor Therapeutics Inc.NCT05846659Phase 2SponsorOncology
May 17, 2026Exicorilant in mCRPC: a fourth failure for the GR-bypass hypothesisExicorilant (CORT125281)NR3C1Corcept TherapeuticsNCT03437941Phase 1/2EfficacyOncology
May 17, 2026Brigimadlin and Brightline-2: Boehringer closes a twenty-year MDM2-p53 betBrigimadlin (BI 907828)MDM2Boehringer IngelheimNCT05512377Phase 2SponsorOncology
May 17, 2026Alpelisib in triple-negative breast cancer: EPIK-B3 ends without a signalAlpelisib (BYL719)PIK3CANovartis PharmaceuticalsNCT04251533Phase 3EnrollmentOncology